Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GPR55 is an atypical cannabinoid-responsive GPCR widely expressed in neural tissue but also present peripherally. Its unique ligand profile—responding both to lipids like LPI and some cannabinoids—alongside distinct signaling mechanisms involving calcium mobilization sets it apart from classical cannabinoid receptors CB1/CB2. Ongoing research continues to clarify its physiological functions and therapeutic potential across neurological disorders, oncology, metabolism/bone health.
Agonist binding leads to activation of G proteins (primarily G13/G12), activation of Rho family GTPases (RhoA, cdc42, rac1), intracellular calcium release, and cytoskeletal rearrangement.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor 55 (GPR55).